From the 512 serums tested by immunocytochemistry on commercial biochips containing transfected HEK293 cells, we identified five multiple sclerosis patients with antibodies against the flotillin-1/2 complex (5/252, 1.98%), whereas none of the control sera tested showed reactivity in cell-based assays (0/260, 0%) (Fig. 2). The gene discussed is FLOT1; the disease is multiple sclerosis.